Johnson & Johnson (NYSE:JNJ) 주식

Johnson & Johnson

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.

citigroup shutter2

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

ERIC

화요일(15일) 미국 지수 선물이 하락세를 보이는 가운데, 투자자들의 주목을 받을 수 있는 주식은 다음과 같다. 시티, 뱅크오브아메리카, 존슨앤드존슨, 유나이티드항공 및 텔레폰악티에볼라예트

화요일 주목해야 할 주식: 시티, 뱅크오브아메리카, 존슨앤드존슨, 유나이티드항공 및 텔레폰악티에볼라예트

Johnson & Johnson Inc. JNJ

Price Target

Analyst Ratings

존슨앤드존슨(NYSE:JNJ)은 4월 15일 화요일 개장 전 1분기 실적을 발표할 예정이다. 애널리스트들은 존슨앤드존슨의 1분기 주당순이익은 전년 동기의 2.71달러보다 낮은 2.58달러로 예상한다. 또한 분기 매출은 215억 7천만 달러로 전년 동기의 213억 8천만 달러 대비 증가할 것으로 예상한다. 

존슨앤드존슨의 1분기 실적 발표 임박···월가에서 가장 정확한 애널리스트 의견은?

Investors,Analyze,Graph,Data,Stock,Market,Index,Via,Digital,Tablet

NFLX

미국 증시는 이틀 연속 상승세를 보였으나 월요일 미국 지수 선물은 투자자들이 여러 주요 기업의 실적 발표를 기다리는 가운데 혼조세를 나타냈다. 이 기사를 작성하는 현재 S&amp;P 500 선물은 0.17% 하락한 5,431포인트, 나스닥 선물은 0.17% 하락한 18,903포인트, 마지막으로 다우존스 선물은 0.18% 하락한 40,666포인트를 기록 중이다.

미국 지수 선물, 넷플릭스 및 아메리칸 익스프레스 실적 앞두고 하락; 닛케이는 긍정적 심리 속 상승 출발

Three <a href="https://www.benzinga.com/etfs">healthcare-themed ETFs</a> were in sharp spotlight Thursday as the sector got through a wild trading day, fueled by UnitedHealth&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) earnings disappointment and steep stock decline. While insurers weighed down on broad healthcare gauges, a drugmakers rally, led by Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), limited the damage.
Also Read: <a href="https://www.benzinga.com/general/health-care/25/04/44869920/unitedhealth-ceo-says-high-cost-of-us-health-care-simply-not-sustainable">UnitedHealth CEO Says High Cost Of US Health Care &#8216;Simply Not Sustainable&#8217;</a>
ETFs In Spotlight
Health Care Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)
<ol>
<li></li>
</ol>
1-Day Return (Thursday): -0.6%
Top holdings of this fund are Eli Lilly, UnitedHealth, Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>). UnitedHealth dropped 2.4%, spooking XLV early in the session. The ETF trimmed losses, however, as Eli Lilly rallied 14.3% on <a href="https://www.benzinga.com/general/biotech/25/04/44878381/eli-lilly-rallies-over-14-notches-best-day-since-june-2000-on-oral-weight-loss-drug-results-analysts-react">good weight-loss pill trial news</a>, calling out the group&#8217;s internal divergency. Barring Thursday&#8217;s turmoil, though, XLV is off just 1.5% for the year so far and commands a 17x forward-earnings multiple—below its five-year history and the large-cap S&amp;P 500&#8217;s 20x multiple, according to Barron&#8217;s.
iShares U.S. Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>)
<ol start="2">
<li></li>
</ol>
1-Day Performance: +4.6%
IHE surged as investors rotated into large-cap pharma stocks, bolstered by Eli Lilly's rally. The gains came despite a nearly 8% drop in Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), Lilly's rival in the GLP-1 space.
SPDR S&amp;P Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPH#NYSE">XPH</a>)
<ol start="3">
<li></li>
</ol>
1-Day Performance: +2.15%
XPH tracked gains across a broader basket of pharmaceutical names, benefiting from bullish sentiment on drugmakers following Lilly's breakthrough.
Market Context: A Sector Of Contrasts
UnitedHealth&#8217;s <a href="https://www.benzinga.com/general/health-care/25/04/44869920/unitedhealth-ceo-says-high-cost-of-us-health-care-simply-not-sustainable">poor earnings and soft guidance</a> spooked healthcare investors, highlighting how exposed insurers are to firm-specific disappointments and policy-level risks. The 22% decline in the stock not only heavily burdened XLV—where it is the second-largest position—but pulled down peers CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), and Elevance Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) too.
However, the overall message of the day was one of subtlety and not panic. Eli Lilly&#8217;s explosion proved the influence of innovation in developing market-driving catalysts within the health-care sector. It provided the stimulus that helped neutralize weakness within managed care and indicated how investors in ETFs are able to still uncover segments of strength despite sector-wide selloffs.
At the same time, Johnson &amp; Johnson kept its steady pace going with the help of strong earnings.
Device and medical equipment manufacturers like Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), Zimmer Biomet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>), and Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) are also attracting investor attention as Wall Street is wagering on secular demand from the aging population.
Takeaway
The health care industry remains far from monolithic. Thursday&#8217;s ETF action underscored the increasing divide between pressured insurers and pharma names benefiting from innovation tailwinds. For investors in ETFs, the message is simple: thematic selectivity is key. Though political headlines and earnings fluctuations might continue to shock portions of the industry, solid fundamentals within pharma and medtech imply there&#8217;s still ample healthy opportunity to go around.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44876466/the-10k-handbag-hoax-tiktoks-trade-war-puts-luxury-etfs-in-the-hot-seat">The $10K Handbag Hoax? TikTok&#8217;s Trade War Puts Luxury ETFs In The Hot Seat</a></li>
</ul>
Image: Shutterstock/The Image Party

Sector ETFs

ETFs

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

iShares Dow Jones US Pharmaceuticals Index Fund

ETF Shake-Up: UNH's Meltdown Meets LLY's Moonshot

Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide.
It will report its Q1 2025 earnings on April 15. Wall Street analysts expect the company to post EPS of $2.59, down from $2.71 in the prior-year period. According to data from Benzinga Pro, quarterly revenue is expected to be $21.60 billion, up from $21.38 billion a year earlier.
Don't Miss:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li>Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a></li>
</ul>
The 52-week range of Johnson &amp; Johnson stock price was $140.68 to $169.99.
Johnson &amp; Johnson's dividend yield is 3.27%. It paid $4.96 per share in dividends during the last 12 months.
<h2 class="wp-block-heading">The Latest On Johnson &amp; Johnson</h2>
On Jan. 22, the company announced its Q4 2024 earnings, posting adjusted EPS of $2.04, beating the consensus of $2.01, as reported by <a href="https://www.benzinga.com/25/01/43125966/johnson-johnson-reports-q4-earnings-above-wall-street-estimates-driven-by-strong-cancer-drugs-revenue">Benzinga</a>. The pharmaceutical giant reported sales of $22.52 billion, up 5.3% year-over-year and beating the consensus of $22.44 billion.
The company expects full-year 2025 sales in the range of $90.9 billion to $91.7 billion, compared to the consensus of $90.99 billion. Full-year adjusted EPS is seen at $10.75 to $10.95, compared to the consensus estimate of $10.59.
Check out this <a href="https://www.benzinga.com/insights/analyst-ratings/25/04/44617177/what-13-analyst-ratings-have-to-say-about-johnson-johnson">article by Benzinga</a> for 13 analysts' insights on Johnson &amp; Johnson.
Trending: It&#8217;s no wonder Jeff Bezos holds over $250 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a>
<h2 class="wp-block-heading">How Can You Earn $100 Per Month As A Johnson &amp; Johnson Investor?</h2>
If you want to make $100 per month — $1,200 annually — from Johnson &amp; Johnson dividends, your investment value needs to be approximately $36,697, which is around 242 shares at $151.73 each.&nbsp;
Understanding the dividend yield calculations: When making an estimate, you need two key variables — the desired annual income ($1,200) and the dividend yield (3.27% in this case). So, $1,200 / 0.0327 = $36,697 to generate an income of $100 per month.
You can calculate the dividend yield by dividing the annual dividend payments by the current price of the stock.
The dividend yield can change over time. This is the outcome of fluctuating stock prices and dividend payments on a rolling basis.
See Also: Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.
For instance, assume a stock that pays $2 as an annual dividend is priced at $50. Its dividend yield would be $2/$50 = 4%. If the stock price rises to $60, the dividend yield drops to 3.33% ($2/$60). A drop in stock price to $40 will have an inverse effect and increase the dividend yield to 5% ($2/$40).
In summary, income-focused investors may find Johnson &amp; Johnson stock an attractive option for making a steady income of $100 per month by owning 242 shares of stock. There may be more upside to come as investors benefit from the company's consistent dividend hikes. Johnson &amp; Johnson has raised its dividend consecutively for the last 62 years.&nbsp;
Read Next:
<ul>
<li>With shares starting at $1.52, <a href="https://www.benzinga.com/money/how-a-10k-bet-on-health-care-originals-could-have-skyrocketed-your-portfolio">this could be your chance to invest in the future of healthcare</a>.</li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>
Image: Shutterstock

Personal Finance

How To Put $100 In Your Retirement Fund Each Month With Johnson & Johnson Stock

Barclays analyst Matt Miksic maintains Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with a Equal-Weight and lowers the price target from $166 to $165.

Barclays Maintains Equal-Weight on Johnson & Johnson, Lowers Price Target to $165

US President Donald Trump issued a multi-part executive order on Tuesday to lower drug prices and <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">reduce Medicare costs</a>.
Within 60 days, the Secretary of Health and Human Services is instructed to seek guidance for the Medicare Drug Price Negotiation Program for initial price applicability year 2028 and how drugmakers should implement the set prices in 2026, 2027, and 2028.
<ul>
<li>This guidance will focus on greater transparency, selecting high-cost drugs, and safeguarding pharmaceutical innovation.</li>
<li>Additionally, the administration seeks to eliminate a key disparity in how Medicare treats small-molecule drugs compared to biologics, discouraging investment in more affordable treatments.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44724763/pharma-industry-faces-jitters-as-trump-hints-at-historic-tariffs-bofa-outlines-probable-timeline" rel="noreferrer noopener">Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline</a>
The White House is also <a target="_blank" href="https://www.whitehouse.gov/presidential-actions/2025/04/lowering-drug-prices-by-once-again-putting-americans-first/" rel="noreferrer noopener">targeting</a> the rising costs seniors face under Medicare. A new payment model will be tested within a year to obtain better value for high-cost drugs and biologicals, including those not subject to price negotiations.
Further, the administration wants to align Medicare payments with actual hospital acquisition costs through a national survey, with potential reimbursement adjustments following the results.
To reform Medicaid drug pricing, the administration will develop recommendations linking drug payments to their value and ensuring accurate rebate payments from manufacturers. The initiative also aims to assist states in managing spending while promoting innovation in Medicaid reimbursement.
Affordability for life-saving medications is another key focus: Community health centers will be required to offer insulin and epinephrine at or below discounted 340B prices to low-income individuals with high out-of-pocket costs or no insurance, with compliance tied to eligibility for future federal grants..
To address price manipulation in the supply chain, the administration calls for reevaluating middlemen roles, such as pharmacy benefit managers, and seeking transparency in their compensation structures. Within 90 days, recommendations to promote a more efficient pharmaceutical market are expected.
Other planned reforms include accelerating FDA approvals for generics and over-the-counter conversions, streamlining the drug importation program, and ensuring Medicare payments do not incentivize hospital-based care over less costly physician offices.
Lastly, federal agencies will investigate anti-competitive practices by drug manufacturers, with public listening sessions and policy recommendations expected within six months.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44826592/netflix-wants-to-be-the-next-1-trillion-company-analyst-highlights-growth-path" target="_blank" rel="noreferrer noopener">Netflix Wants To Be The Next $1 Trillion Company, Analyst Highlights Growth Path</a></li>
</ul>
Photo by Aria Armoko via Shutterstock

Biotech

Government

Regulations

Health Care

General

ABBV

BIIB

BMRN

GILD

REGN

VRTX

Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction

Raymond James analyst Jayson Bedford maintains Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with a Outperform and raises the price target from $162 to $164.

Raymond James Maintains Outperform on Johnson & Johnson, Raises Price Target to $164

Johnson &amp; Johnson's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) short percent of float has fallen 22.33% since its last report. The company recently reported that it has 19.15 million shares sold short, which is 0.8% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.28 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Johnson &amp; Johnson Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744819222_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Johnson &amp; Johnson has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Johnson &amp; Johnson's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Johnson &amp; Johnson's peer group average for short interest as a percentage of float is 4.00%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Johnson & Johnson?

Morgan Stanley analyst Terence Flynn maintains Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with a Equal-Weight and raises the price target from $164 to $169.

Morgan Stanley Maintains Equal-Weight on Johnson & Johnson, Raises Price Target to $169

RBC Capital analyst Shagun Singh reiterates Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with a Outperform and maintains $181 price target.

Reiteration

RBC Capital Reiterates Outperform on Johnson & Johnson, Maintains $181 Price Target

Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) reported <a href="https://www.benzinga.com/general/biotech/25/04/44812561/johnson-johnson-q1-earnings-strong-cancer-drug-sales-boosts-quarterly-dividend-anticipates-negative-currency-impact-for-2025-profit">upbeat first-quarter results</a> on Wednesday.
Here are some key analyst takeaways.
Goldman Sachs On Johnson &amp; Johnson
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/67f5483f584c820001291ac6/asad-haider%20">Analyst Asad Haider</a> maintained a Buy rating and price target of $172.
Despite Stelara sales declining due to the arrival of biosimilars in the market, the company reported impressive results across the Innovative Medicines business, Haider said in a note. The results and guidance highlight the power of the company's pharma portfolio, with upside drivers comprising "established products across the company's industry-leading multiple myeloma franchise, the Immunology franchise, as well emerging new product-cycles that we are monitoring in oncology and neuroscience." 
Management raised its full-year sales guidance by $1.8 billion at the midpoint to a range of $91.0 billion to $91.8 billion, Haider stated. He expects the company to outperform the current consensus for sales in 2025 and 2026.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
RBC Capital Markets On Johnson &amp; Johnson
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/606ed90d9e63ea0001ef8211/shagun-singh">Analyst Shagun Singh</a> reiterated an Outperform rating and price target of $181.
Although Johnson &amp; Johnson reported its sales and earnings ahead of expectations, its stock declined due to lower-than-expected MedTech growth and gross margins missing consensus by 290 basis points, Singh said.
"JNJ quantified tariff exposure ($400MM or 1.9% of MedTech sales, no pharma) that gave investors some reprieve and also indicated that healthcare is fairly recession-proof with no signs yet of an impact on elective procedures or prescription coverage," the analyst wrote. Management's 2025 guidance reflected healthy earnings growth of 6.2% despite Stelara's loss of exclusivity, he added.
Guggenheim Securities On Johnson &amp; Johnson
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/586e48c6351b9b00018beef0/steven-forbes">Analyst Steven Forbes</a> reaffirmed a Neutral rating on the stock.
Johnson &amp; Johnson reported first-quarter sales of $21.89 billion, beating consensus of $21.56 billion, and earnings of $2.77 per share surpassing consensus of $2.58 per share, Forbes said. "The beat appears to be mainly driven by higher total revenue, lower R&amp;D and SG&amp;A expenses, and higher interest and other income," he added.
The Innovative Medicines segment delivered a strong performance, while Stelara and the Invega products performed below expectations. "We do not believe the 1Q 2025 results fundamentally change the overall JNJ story, with investors likely focusing more on current macro factors (e.g., tariffs, taxes, healthcare utilization, etc&#8230;), and their impact on JNJ and its peers, and potentially less focus than usual on JNJ&#8217;s current growth drivers and pipeline assets," Forbes wrote.
JNJ Price Action: Shares of Johnson &amp; Johnson had declined by 0.47% to $152.90&nbsp;at the time of publication on Wednesday.
Read More: <a href="https://www.benzinga.com/25/04/44634737/retailers-brace-for-higher-costs-as-us-tariff-rates-soar-says-goldman-sachs">2 Under-the-Radar Consumer Staples Stocks With Big Dividends</a>
Photo: Shutterstock

Analyst Color

Earnings Beats

Johnson & Johnson's Q1 Results, FY Guidance Highlight The 'Power Of The Pharma Portfolio'

Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), on Tuesday, reported a first-quarter 2025 adjusted EPS of $2.77, up 2.2% year over year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $2.60</a>.
The pharmaceutical giant reported sales of $21.89 billion, up 2.4% year over year and beating the consensus&nbsp;<a target="_blank" href="https://www.benzinga.com/25/04/44806571/johnson-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts" rel="noreferrer noopener">of $21.58 billion</a>.
Operational growth was 4.2%, and adjusted operational growth was 3.3%. Innovative Medicine sales increased 2.3% or 4.2 operationally to $13.90 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44737545/johnson-johnson-protagonist-partnered-investigational-psoriasis-oral-pill-shows-75-of-adolescents-achieved-completely-clear-skin" rel="noreferrer noopener">Johnson &amp; Johnson, Protagonist Tout Positive Results For Psoriasis Oral Pill Study</a>
Growth was driven by Darzalex (daratumumab), Carvykti (ciltacabtagene autoleucel), Erleada (apalutamide), Rybrevant/Lazcluze in oncology, Tremfya (guselkumab) and Simponi/Simponi Aria in immunology, Spravato (esketamine) Neuroscience, and Xarelto in cardiovascular. Growth was partially offset by an approximate (810) basis points impact from Stelara <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44808099/johnson-johnson-reports-q1-2025-results" rel="noreferrer noopener">(ustekinumab) in immunology</a>.
Cancer sales increased to $5.68 billion, up 17.9% (+20.4 operational).
Immunology sales fell to $3.71 billion, down 12.7% (down 10.9% operational).
Stelara sales&nbsp;<a target="_blank" href="https://s203.q4cdn.com/636242992/files/doc_financials/2025/q1/1Q25-Earnings-Press-Release-Final-Draft-4-14-with-Attachments.pdf" rel="noreferrer noopener">fell</a> 33.7% to $1.63 billion. Darzalex sales rose 20.3% to $3.24 billion. The company&#8217;s cancer cell therapy, Carvykti, generated sales of $369 million.
MedTech sales increased 2.5% to 8.02 billion, driven primarily by Abiomed in cardiovascular and wound closure products in general surgery. Growth was partially offset by Spine, Sports &amp; Other in Orthopaedics.
Dividend: Johnson &amp; Johnson also announced an increase in its quarterly dividend from $1.24 to $1.30 per share. The 4.8% increased dividend is payable on June 10, with a record date of May 27.
Guidance:&nbsp;Johnson &amp; Johnson expects 2025 sales of $91 billion-$91.8 billion versus <a target="_blank" href="https://www.benzinga.com/25/01/43125966/johnson-johnson-reports-q4-earnings-above-wall-street-estimates-driven-by-strong-cancer-drugs-revenue" rel="noreferrer noopener">prior guidance of $90.9 billion–$91.7 billion</a> and consensus of $90.62 billion
The Medtech giant expects 2025 adjusted operational EPS of $10.50-$10.70, compared to prior guidance of $10.75–$10.95. It maintained the adjusted EPS outlook of $10.50-$10.70 versus the consensus of $10.50.
Adjusted operational EPS excluded the impact of translational currency, which means JNJ anticipates a hit to the bottomline from the impact currency.
The company anticipates second-half operational <a href="https://s203.q4cdn.com/636242992/files/doc_financials/2025/q1/Final-JNJ-Earnings-Presentation-Q1-2025-Webcast.pdf" target="_blank" rel="noreferrer noopener">sales</a> growth higher than the first half of 2025. 
Johnson &amp; Johnson said the increase in full-year 2025 operational sales&nbsp;guidance reflects the addition of CAPLYTA following the completion of the Intra-Cellular Therapies acquisition.
Including tariff costs, dilution from the Intra-Cellular Therapies acquisition, and updated foreign exchange, the company maintains a full-year 2025 adjusted reported EPS&nbsp;outlook of 6.2% growth at the mid-point.
In March, Johnson &amp; Johnson&nbsp;announced its plans to invest more than&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/equities/25/03/44433978/johnson-johnson-to-invest-55-billion-in-us-to-boost-manufacturing-drug-discovery" rel="noreferrer noopener">$55 billion in the U.S. over the next four years</a>.
Price Action: JNJ stock is down 0.88% at $153.01&nbsp;during the premarket session at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44801588/bofa-sees-mostly-inline-q1-for-industrials-highlights-3m-jci-ge-vernova-as-top-picks" target="_blank" rel="noreferrer noopener">BofA Sees Mostly Inline Q1 For Industrials, Highlights 3M, JCI, GE Vernova As Top Picks</a></li>
</ul>
Photo via Shutterstock

Large Cap

Guidance

Dividends

Johnson & Johnson Q1 Earnings: Strong Cancer Drug Sales, Boosts Quarterly Dividend, Anticipates Negative Currency Impact For 2025 Profit

Net trade sales were $1.829 billion in the U.S. and $1.409 billion in the rest of the world. Genmab receives royalties on the worldwide net sales of DARZALEX, both the intravenous and SC products, under the exclusive worldwide license to J&amp;J to develop, manufacture and commercialize daratumumab.&nbsp;&nbsp;

GMAB

Genmab Announces Net Sales Of DARZALEX (daratumumab) For Q1: Says Net sales Of DARZALEX Totaled $3.237B, Co Received Royalties On Worldwide Net Sales From Johnson & Johnson

Johnson & Johnson Declared 4.8% Increase In The Quarterly Dividend, From $1.24 Per Share To $1.30, Payable On June 10 To Shareholders Of Record At The Close Of Business On May 27

Johnson & Johnson Expects 2025 Adjusted EPS Of $10.50-$10.70 Versus Prior Guidance Of $10.75–$10.95 And Consensus Of $10.46

<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">($ in Billions, except EPS)</td>
<td colspan="1" rowspan="1">April 2025</td>
<td colspan="1" rowspan="1">January 2025</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Adjusted Operational Sales1,2,5
Change vs. Prior Year / Mid-point
</td>
<td colspan="1" rowspan="1">2.0% – 3.0% / 2.5%</td>
<td colspan="1" rowspan="1">2.0% – 3.0% / 2.5%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Operational Sales2,5 / Mid-point
Change vs. Prior Year / Mid-point
</td>
<td colspan="1" rowspan="1">
$91.6B – $92.4B / $92.0B
3.3% – 4.3% / 3.8%
</td>
<td colspan="1" rowspan="1">
$90.9B – $91.7B / $91.3B
2.5% – 3.5% / 3.0%
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Estimated Reported Sales3,5/ Mid-point
Change vs. Prior Year / Mid-point
</td>
<td colspan="1" rowspan="1">
$91.0B – $91.8B / $91.4B
2.6% – 3.6% / 3.1%
</td>
<td colspan="1" rowspan="1">
$89.2B – $90.0B / $89.6B
0.5% – 1.5% / 1.0%
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Adjusted Operational EPS (Diluted)2,4 / Mid-point
Change vs. Prior Year / Mid-point
</td>
<td colspan="1" rowspan="1">
$10.50 – $10.70 / $10.60
5.2% – 7.2% / 6.2%
</td>
<td colspan="1" rowspan="1">
$10.75 – $10.95 / $10.85
7.7% – 9.7% / 8.7%
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Adjusted EPS (Diluted)3,4 / Mid-point
Change vs. Prior Year / Mid-point
</td>
<td colspan="1" rowspan="1">
$10.50 – $10.70 / $10.60
5.2% – 7.2% / 6.2%
</td>
<td colspan="1" rowspan="1">
$10.50 – $10.70 / $10.60
5.2% – 7.2% / 6.2%
</td>
</tr>
</tbody>
</table>
</figure>

Johnson & Johnson Expects 2025 Sales Of $91B-$91.8B Versus Prior Guidance Of $90.9B–$91.7B And Consensus Of $90.62B

Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) reported quarterly earnings of $2.77 per share which beat the analyst consensus estimate of $2.60 by 6.54 percent. This is a 2.21 percent increase over earnings of $2.71 per share from the same period last year. The company reported quarterly sales of $21.89 billion which beat the analyst consensus estimate of $21.58 billion by 1.47 percent. This is a 2.39 percent increase over sales of $21.38 billion the same period last year.

Johnson & Johnson Q1 2025 Adj EPS $2.77 Beats $2.60 Estimate, Sales $21.89B Beat $21.58B Estimate

U.S. stock futures were volatile on Tuesday following a two-day advance. Futures of major benchmark indices were mixed in premarket.
Donald Trump hinted at helping the car companies while talking to reporters in his Oval Office on Monday. He explained that automakers require a transition period to shift production from Canada, Mexico, and elsewhere.
&#8220;And they need a little bit of time because they're going to make them here, but they need a little bit of time. So I'm talking about things like that,&#8221; he said.
Stocks advanced for two consecutive days after he exempted smartphones, computers, and semiconductors from the reciprocal tariffs on Friday. However, he hinted that he may look at levying duties on the chips imported into the U.S. on Sunday in a Truth Social post.
The 10-year Treasury bond yielded 4.38% and the two-year bond was at 3.86%. The CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>&#8216;s projections show markets pricing an 82.7% likelihood of the Federal Reserve keeping the current interest rates unchanged in its May meeting. 
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.03%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.08%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>0.25%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.12%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, rose in premarket on Tuesday. The SPY was up 0.013% to $539.19, while the QQQ advanced 0.22% to $458.47, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From Last Session:
Led by technology stocks, U.S. equities closed higher on Monday. Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) shares surged 2.2%, and Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELLL#NYSE">DELLL</a>) gained approximately 4%, contributing to a roughly 1% rise in the Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>).
Financials presented a mixed picture, with Goldman Sachs Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) reporting stronger-than-anticipated first-quarter earnings, while M&amp;T Bank Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTB#NYSE">MTB</a>) posted weaker-than-expected results.
Real estate, utilities, and consumer staples sectors recorded the most significant gains on Monday. Conversely, consumer discretionary stocks trended lower.
As of Monday&#8217;s close, the Dow Jones index was 10.1% lower than its 52-week high of 45,073.63 points. The S&amp;P 500 index was 12.06% lower than its previous high of 6,147.43 points, and the Nasdaq 100 index was down 15.42% from its last record high of 22,222.61 points.
The Dow Jones index climbed 312 points or 0.78% to 40,524.79, whereas the S&amp;P 500 index advanced 0.79% to 5,405.97. Nasdaq Composite rose to end 0.64% higher at 16,831.48, and the small-cap gauge, Russell 2000, jumped 1.11% to 1,880.88.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>0.64%</td>
<td>16,831.48</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.79%</td>
<td>5,405.97</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.78%</td>
<td>40,524.79</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1.11%</td>
<td>1,880.88</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
Ark Invest CEO Cathie Wood said that she sees a &#8220;light at the end of the tunnel,&#8221; despite the ongoing<a href="https://www.benzinga.com/government/regulations/25/04/44807265/cathie-wood-says-shock-therapy-from-trumps-trade-moves-may-end-prolonged-economic-slump"> tariff turmoil</a>. According to Wood, tariffs could be the catalyst to end a three-year "rolling recession."
She said that Trump&#8217;s decision to bring Treasury Secretary Scott Bessent into the process indicates a move to reduce both tariffs and non-tariff trade obstacles. She contends this shift wouldn&#8217;t have occurred without the initial &#8220;shock therapy&#8221; of aggressive trade measures.
The slowdown caused by the tariff introduction will give the administration and the Federal Reserve "more degrees of freedom to stimulate than most investors have been expecting,&#8221; she said.
This will create a "clarion call" for tax cuts, deregulation, and lower interest rates, ultimately paving the way for economic recovery, Wood added.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">While the last two weeks of tariff turmoil have been challenging for financial markets, we see light at the end of the tunnel! <a href="https://t.co/cexMNdtbLp">https://t.co/cexMNdtbLp</a>
&mdash; Cathie Wood (@CathieDWood) <a href="https://twitter.com/CathieDWood/status/1911969728337186973?ref_src=twsrc%5Etfw">April 15, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The analysts at BlackRock extended their tactical horizon back to six to 12 months and resumed their positive view on U.S., while still expecting the &#8220;ongoing risk asset volatility and potentially sharp reversals.&#8221;
Spiking yields in long-term U.S. Treasuries seemed to be a factor in the change in tariff tactics, the weekly note stated.
&#8220;We stay underweight long-term Treasuries, our highest conviction view: tariffs are likely to add to already sticky inflation, and congressional budget plans last week reinforce the outlook for persistent budget deficits. We favor gold instead as a portfolio diversifier.&#8221;
According to BlackRock, the broad-based equity selloff has created opportunities to tap into certain sectors, and &#8220;selectivity is key.&#8221;
&#8220;We still like U.S. technology benefitting from the AI buildout and adoption. We also favor global banks. That includes U.S. banks given the scope for deregulation even with some potential economic pain.&#8221;
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures </a>
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on Tuesday:
<ul>
<li>March&#8217;s import price index data and April&#8217;s Empire State manufacturing survey data will be released by 8:30 a.m. ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Citigroup Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>) rose 1.09% in premarket on Tuesday as it is expected to report earnings before the opening bell. Analysts expect a quarterly earnings of $1.85 per share on revenue of $21.29 billion.</li>
</ul>
<ul>
<li>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) was down 0.29% as Wall Street expects it to report earnings of $2.60 per share on revenue of $21.58 billion before the opening bell.</li>
</ul>
<ul>
<li>Bank of America Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) was up 0.76% as it is expected to report earnings before the opening bell. Analysts expect a quarterly earnings of 82 cents per share on revenue of $26.99 billion.</li>
</ul>
<ul>
<li>United Airlines Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) declined 0.12% as Wall Street expects it to report earnings of 76 cents per share on revenue of $13.26 billion after the closing bell.</li>
</ul>
<ul>
<li>Telefonaktiebolaget LM Ericsson ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIC#NASDAQ">ERIC</a>) jumped 6.17% after reporting that its first-quarter adjusted operating earnings, excluding restructuring charges, jumped 44% year-over-year to 6.2 billion Swedish crowns ($636 million).</li>
</ul>
<ul>
<li>Lowe&#8217;s Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>) advanced by 0.58% as it announced the purchase of an interior design company, Artisan Design Group, for $1.3 billion.</li>
</ul>
<ul>
<li>ARB IOT Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBB#NASDAQ">ARBB</a>) surged 33.83% after securing a $53 million deal to provide AI servers to Whizzl Group, boosting its AI infrastructure presence and strengthening its position in the AI and data center markets.</li>
</ul>
<ul>
<li>Geovax Labs Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) slumped 34.57% after it was directed by the Biomedical Advanced Research and Development Authority on April 11 to halt its Phase 2b COVID-19 vaccine trial.</li>
</ul>
Commodities, Gold, And Global Equity Markets:
Crude oil futures were trading lower in the early New York session by 0.29% to hover around $61.35 per barrel.
Gold Spot US Dollar advanced 0.46% to hover around $3,223.97 per ounce. Its fresh record high stood at $3,245.84 per ounce. The U.S. Dollar Index spot was lower by 0.06% at the 99.585 level.
Asian markets rose on Tuesday, including India's S&amp;P BSE Sensex, China&#8217;s CSI 300, Hong Kong's Hang Seng, Japan's Nikkei 225, Australia's ASX 200, and South Korea's Kospi index. European markets were also higher in early trade.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44807265/cathie-wood-says-shock-therapy-from-trumps-trade-moves-may-end-prolonged-economic-slump">Cathie Wood Says &#8216;Shock Therapy&#8217; From Trump&#8217;s Trade Moves May End Prolonged Economic Slump</a></li>
</ul>
Image Via Shutterstock

Equities

Economics

Federal Reserve

AAPL

ARBB

DELLL

GOVX

US Stock Futures Waver After Two-Day Rally: Trump's Tariff Moves Could End A 3-Year 'Rolling Recession,' Says Expert

With U.S. stock futures trading lower this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects Citigroup Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>) to report quarterly earnings at $1.85 per share on revenue of $21.29 billion before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Citigroup shares rose 0.4% to $63.49 in after-hours trading.</li>
<li>Analysts are expecting Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) to post quarterly earnings at $2.60 per share on revenue of $21.58 billion. The company will release earnings before the markets open. Johnson &amp; Johnson shares fell 0.6% to $153.50 in after-hours trading.</li>
<li>Telefonaktiebolaget LM Ericsson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIC#NASDAQ">ERIC</a>) reported that its first-quarter adjusted operating earnings, excluding restructuring charges, jumped 44% year-over-year to 6.2 billion Swedish crowns ($636 million). Its net sales rose 3% year-over-year to 55 billion crowns during the quarter. Ericsson shares gained 1.3% to $7.55 in the after-hours trading session.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>After the markets close, United Airlines Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) is projected to post quarterly earnings at 76 cents per share on revenue of $13.26 billion. United Airlines shares fell 0.3% to $65.49 in after-hours trading.</li>
<li>Analysts expect Bank of America Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) to post quarterly earnings at 82 cents per share on revenue of $26.99 billion before the opening bell. Bank of America shares gained 0.4% to $36.83 in after-hours trading.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44787747/wall-streets-most-accurate-analysts-spotlight-on-3-consumer-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Consumer Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Citigroup, Bank Of America And 3 Stocks To Watch Heading Into Tuesday

<h3>Companies Reporting Before The Bell</h3>
• Albertsons Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACI#NYSE">ACI</a>) is estimated to report quarterly earnings at $0.40 per share on revenue of $18.79 billion. 
• Bank of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) is expected to report quarterly earnings at $0.82 per share on revenue of $26.99 billion. 
• PNC Financial Services Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNC#NYSE">PNC</a>) is estimated to report quarterly earnings at $3.38 per share on revenue of $5.48 billion. 
• Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) is projected to report quarterly earnings at $2.60 per share on revenue of $21.57 billion. 
• Telefonaktiebolaget L M (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIC#NASDAQ">ERIC</a>) is projected to report quarterly earnings at $0.09 per share on revenue of $5.10 billion. 
• Zhibao Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBAO#NASDAQ">ZBAO</a>) is projected to report earnings for its first quarter. 
• Citigroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>) is projected to report quarterly earnings at $1.85 per share on revenue of $21.29 billion. 
• Rent the Runway (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RENT#NASDAQ">RENT</a>) is expected to report quarterly loss at $2.25 per share on revenue of $77.60 million. 
<h3>Companies Reporting After The Bell</h3>
• Equity Bancshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQBK#NYSE">EQBK</a>) is expected to report quarterly earnings at $0.83 per share on revenue of $56.69 million. 
• Fulton Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FULT#NASDAQ">FULT</a>) is estimated to report quarterly earnings at $0.43 per share on revenue of $314.85 million. 
• Beeline Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLNE#NASDAQ">BLNE</a>) is estimated to report earnings for its fourth quarter. 
• JB Hunt Transport Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBHT#NASDAQ">JBHT</a>) is expected to report quarterly earnings at $1.14 per share on revenue of $2.90 billion. 
• Omnicom Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMC#NYSE">OMC</a>) is projected to report quarterly earnings at $1.66 per share on revenue of $3.72 billion. 
• Banzai International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNZI#NASDAQ">BNZI</a>) is likely to report quarterly loss at $8.00 per share on revenue of $1.49 million. 
• Interactive Brokers Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBKR#NASDAQ">IBKR</a>) is likely to report quarterly earnings at $1.93 per share on revenue of $1.41 billion. 
• United Airlines Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) is likely to report quarterly earnings at $0.76 per share on revenue of $13.26 billion. 
• Pioneer Power Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPSI#NASDAQ">PPSI</a>) is projected to report quarterly loss at $0.42 per share on revenue of $9.80 million. 
• Hancock Whitney (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HWC#NASDAQ">HWC</a>) is likely to report quarterly earnings at $1.29 per share on revenue of $367.96 million. 
• GameSquare Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAME#NASDAQ">GAME</a>) is expected to report quarterly loss at $0.08 per share on revenue of $42.75 million. 
• Kore Group Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KORE#NYSE">KORE</a>) is expected to report quarterly loss at $0.44 per share on revenue of $70.30 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BLNE

BNZI

EQBK

FULT

GAME

IBKR

JBHT

KORE

PPSI

RENT

ZBAO

Earnings Scheduled For April 15, 2025

Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) will release earnings results for the first quarter, before the opening <a href="https://www.benzinga.com/quote/jnj/earnings">bell on Tuesday, April 15.</a>
Analysts expect the New Brunswick, New Jersey-based company to report quarterly earnings at $2.58 per share, down from $2.71 per share in the year-ago period. Johnson &amp; Johnson projects to report quarterly revenue at $21.57 billion, compared to $21.38 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Protagonist Therapeutics, on April 10, announced new data for a pill that treats moderate-to-severe plaque psoriasis. The Phase 3 study was conducted in adolescents and adults simultaneously. The ICONIC program, with icotrokinra (JNJ-2113) data from a subgroup analysis, came about through a partnership with Johnson &amp; Johnson.
Johnson &amp; Johnson shares gained 1.7% to close at $154.36 on Monday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/JNJ/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Raymond James analyst Jayson Bedford maintained an Outperform rating and cut the price target from $165 to $162 on April 14, 2025. This analyst has an accuracy rate of 69%.</li>
<li>Morgan Stanley analyst Terence Flynn maintained an Equal-Weight rating and raised the price target from $163 to $164 on April 9, 2025. This analyst has an accuracy rate of 66%.</li>
<li>Guggenheim analyst Vamil Divan reiterated a Neutral rating on April 2, 2025. This analyst has an accuracy rate of 72%.</li>
<li>Barclays analyst Matt Miksic maintained an Equal-Weight rating and increased the price target from $159 to $166 on Jan. 28, 2025. This analyst has an accuracy rate of 66%.</li>
<li>Stifel analyst Rick Wise maintained a Hold rating and slashed the price target from $170 to $155 on Jan. 23, 2025. This analyst has an accuracy rate of 73%.</li>
</ul>
Considering buying JNJ stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="581" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15033215/image-102-1024x581.png" alt="" class="wp-image-871481" style="width:540px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15033215/image-102-1024x581.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15033215/image-102-300x170.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15033215/image-102-768x435.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15033215/image-102.png 1097w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44787747/wall-streets-most-accurate-analysts-spotlight-on-3-consumer-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Consumer Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Johnson & Johnson Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

After two days of back-to-back gains in the spot market, U.S. stock futures had a choppy session Monday night as investors await earnings reports from multiple prominent companies.
The S&amp;P 500 Futures are down 0.17% at 5,431, followed by Nasdaq Futures at 18,903 down 0.17%, and finally, Dow Jones Futures are down 0.18% at 40,666, at the time of writing this.
Asian markets opened higher, with Japan&#8217;s benchmark Nikkei 225 up 1.16% or 393 points in early morning trade, driven by tech, automotive, and export-linked stocks, aided by strong positive sentiments from a rebound in global equity markets.
See More: <a href="https://www.benzinga.com/news/management/25/04/44802094/tariff-fears-pose-material-risks-to-us-and-global-economies-goldman-sachs-ceo-warns">Tariff Fears Pose &#8216;Material Risks&#8217; To US And Global Economies, Goldman Sachs CEO Warns</a>
The U.S. Dollar Index (DXY) rebounded from its multi-year lows on Monday night, up 0.24% at 99.88, after reaching a high of 99.67 during the day. 
Despite the relief to the electronics and semiconductors industries by the U.S. Government by announcing an <a href="https://benzinga.com/25/04/44778464/trump-administration-grants-tariff-reprieve-to-tech-industry-apple-and-nvidia-among-beneficiaries">exemption for reciprocal tariffs</a>, markets remain under the grip of uncertainty, with Commerce Secretary Howard Lutnick announcing on Sunday that this reprieve might only be temporary.
Markets are also on the edge with several big names set to announce their earnings this week, such as Bank of America Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>), Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), Citigroup Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>), American Express Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>), and Netflix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>), among several others.
Photo Courtesy: Gumbariya On Shutterstock.com
Read More: 
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44801373/a-us-recession-in-2025-betting-odds-say-its-more-likely-than-not">A US Recession In 2025? Betting Odds Say It&#8217;s More Likely Than Not</a></li>
</ul>

US Stock Futures Slip As Investors Brace Themselves For Netflix, AmEx Earnings This Week — Nikkei Up On Strong Sentiment

Press Releases

Johnson & Johnson Announces Expected Closing Date for Intra-Cellular Acquisition

Johnson & Johnson Closes Landmark Intra-Cellular Therapies, Inc. Acquisition to Solidify Neuroscience Leadership

TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to significantly reduce both the signs and symptoms and the progression of structural damage in adults living with active psoriatic arthritis

Johnson & Johnson to Participate in the BofA Securities 2025 Healthcare Conference

Johnson & Johnson highlights new data that showcase the strength of nipocalimab, demonstrating long-term sustained disease control in adults living with generalized myasthenia gravis (gMG)

Icotrokinra results show 75% of adolescents with plaque psoriasis achieved completely clear skin and demonstrate favorable safety profile in a once daily pill

Johnson & Johnson Reports Q1 2025 Results

Johnson & Johnson Announces 63rd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.8%

NYSE Content Advisory: Pre-Market update + Bank of America beats earnings estimates

Johnson & Johnson to Participate in the 2025 RBC Capital Markets Global Healthcare Conference

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Verona Pharma

Viatris

Zoetis

Barclays

Raymond James

Morgan Stanley

RBC Capital

B of A Securities

Screenshot 2024-09-30 at 9.13.36 PM

TNXP

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-04-30 at 5.36.02 PM

Cardio Diagnostics Holdings Inc. - Common stock

Comments

Johnson & Johnson

뉴스

파트너 / 기고자

벤징가 글로벌